panitumumab, mytomicin C, 5-FU, radiation
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anal Squamous Cell Carcinoma
Conditions
Anal Squamous Cell Carcinoma
Trial Timeline
Oct 1, 2010 → Mar 24, 2017
NCT ID
NCT01285778About panitumumab, mytomicin C, 5-FU, radiation
panitumumab, mytomicin C, 5-FU, radiation is a phase 2 stage product being developed by Amgen for Anal Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01285778. Target conditions include Anal Squamous Cell Carcinoma.
What happened to similar drugs?
6 of 12 similar drugs in Anal Squamous Cell Carcinoma were approved
Approved (6) Terminated (0) Active (6)
🔄HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01285778 | Phase 2 | Completed |
Competing Products
20 competing products in Anal Squamous Cell Carcinoma